FDA Pathways, Simplified
If you are building a medtech company, one of the first big questions you may have is: what FDA pathway applies to my medical device? The applicable regulatory pathway may affect your timeline, evidence plan, budget and go-to-market strategy, so understanding it early can save real time and money.
The good news is that most products fit into a small group of core pathways. In simple terms, 510(k), De Novo, and Pre-Market Authorization (PMA) are the main routes to market, while Breakthrough, STeP, RAPID, TAP and TEMPO are programs that may help certain products move more efficiently through these pathways by providing support in development, review, evidence generation and/or or coverage planning.
The main pathways
The 510(k) pathway is usually the best fit when a device is similar enough to an existing product on the market (i.e., a predicate). For this pathway, the company must demonstrate that the subject device is substantially equivalent to the predicate with respect to intended use and technological characteristics. The testing required for this pathway is generally based on what is conducted for the clearance of the predicate. For many moderate-risk devices and some diagnostics, the 510(k) pathway is the most common route.
The De Novo pathway is for products that are novel in technological characteristics and/or intended use and do not have a suitable predicate but are still considered low to moderate risk. Depending on the risks associated with the device, a De Novo may require animal or clinical study data to show safety and efficacy. If FDA grants a De Novo request, that product type gets a new classification that future companies may later use as the basis for a 510(k).
The PMA, or Premarket Approval pathway, is generally for high-risk products and requires the strongest evidence package, often requiring a full audit (pre-approval inspection) as well as clinical data to show safety and effectiveness. For startups, this is usually the most demanding route in terms of time, cost, and regulatory effort.
Programs that can help
The Breakthrough Devices Program is not a separate route to market. It is a designation for certain products that are subject to the 510(k), De Novo, or PMA pathways and offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. If their product qualifies for Breakthrough Device Designation (BDD), sponsors have the opportunity to engage with FDA more frequently during specific Pre-Submission meetings known as “sprint discussions.” Additionally, FDA offers support in creating a Data Development Plan (DDP) or Clinical Protocol Agreement. FDA may also provide a prioritized review of regulatory submissions, including Investigational Device Exemption (IDE) applications and marketing submissions.
STeP, or the Safer Technologies Program, works in a similar way but is meant for products that significantly improve the safety of currently available treatments or diagnostics that target conditions that are less serious or more reversible than those covered by BDD. Like Breakthrough, it does not replace the underlying pathway; it is a program layered on top of a 510(k), De Novo or PMA pathways.
RAPID is different because it involves insurance coverage, not FDA authorization alone. The program is intended to help certain devices with BDD move more quickly from FDA authorization to Medicare coverage, which matters because many startups face delays not at approval, but after approval when payment and adoption are still unclear. To be eligible for RAPID, devices must be the subject of an IDE study that enrolls Medicare beneficiaries and studies clinical health outcomes agreed upon by the FDA and Centers for Medicare and Medicaid Services (CMS).
TAP or Total Product Life Cycle Advisory Program is a pilot program initiated to help spur more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health. For your device to be applicable for TAP, you must already have BDD or be in the STeP Program but can’t have engaged in a Pre-Submission interaction following inclusion in either program. Only eligible therapeutic areas can join, which currently includes ophthalmic, cardiovascular, neurological/physical medicine, orthopedic, radiological, renal, GI, obesity, transplant, surgical, and infection control devices. Additional therapeutic areas will be added in the future.
For certain digital health products, TEMPO is also worth watching. TEMPO is an FDA pilot designed to support real-world evidence generation for qualifying digital health technologies in chronic care settings, giving companies a more practical way to gather data while products are being used in the field.
| Pathway | When to use | Risk level | Evidence needed |
|---|---|---|---|
| 510(k) | Similar to existing device | Low-Moderate (Class I/II) | Show “substantial equivalence” to predicate |
| De Novo | Novel, no predicate | Low-Moderate (new Class I/II) | Safety + effectiveness data |
| PMA | High risk | High (Class III) | Clinical trials + strong evidence |
| Program | What it does | Who qualifies |
|---|---|---|
| Breakthrough | Priority FDA review & feedback | Novel devices for life-threatening conditions |
| STeP | Same Similar benefits, safety focus, currently no reimbursement support | Safety improvements, less serious conditions |
| RAPID | Faster Medicare coverage after FDA OK | Breakthrough devices (Class III devices and Class II devices in TAP) |
| TAP | Faster & more frequent communication with FDA | Breakthrough devices & STeP participants in eligible therapeutic areas |
| TEMPO | Real-world evidence for digital health | Chronic care digital products in eligible therapeutic areas |
Why this matters early
For startups, pathway strategy is not just a regulatory issue. It shapes product design, testing, clinical planning, reimbursement strategy, investor expectations and launch timing. The earlier a team understands its likely path, the easier it becomes to build the right evidence and avoid expensive course corrections later.
At Avio Medtech, we help startups identify the appropriate path Day 1 so your journey to market is charted and you can build the right evidence from takeoff. Contact us for assistance navigating your flight plan, or to get started.
